IP Library Granted Patent US 9,468,617
Granted Patent B2
US 9,468,617 · App. 14/568,364 · Granted Oct 18, 2016

Topical pharmaceutical gel composition of diclofenac sodium

Inventor: Bala Chandran Nayar (Somerset, NJ)
Assignee: LUPIN ATLANTIS HOLDINGS SA
A61K31/196A61K9/0014A61K9/06A61K47/02A61K47/10A61K47/14A61K47/183A61K47/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,468,617
App. No.
14/568,364
Granted
Oct 18, 2016
Kind
B2
Abstract

Topical pharmaceutical gel compositions of diclofenac sodium are provided. The topical gel compositions contain at least about 10% w/w diclofenac sodium and are suitable for once-a-day topical application.

Claims (83)

1. A topical pharmaceutical gel composition of diclofenac comprising:

at least about 10% w/w of diclofenac sodium;

about 5-25% w/w of a glycol solvent;

about 1-6% w/w of at least one gelling agent;

about 0.01-0.75% w/w of at least one preservative;

about 0.01-1% w/w of at least one antioxidant;

about 1-10% w/w of a salicylic acid ester;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8, wherein the ratio of the amount of diclofenac sodium to the amount of the salicylic acid ester is about 1:0.1 to about 1:0.5 and/or the ratio of the amount of diclofenac sodium to the amount of menthol is about 1:0.01 to about 1:0.05.

2. The topical gel composition of claim 1 , wherein the glycol solvent is selected from the group consisting of propylene glycol, polyethylene glycol, ethylene glycol, butylene glycol, and hexylene glycol.

3. The topical gel composition of claim 2 , wherein the glycol solvent is propylene glycol.

4. The topical gel composition of claim 1 , wherein the at least one gelling agent is selected from the group consisting of carbomers, xanthan gum, acacia, tragacanth, sodium alginate, gelatin, modified starches, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, methyl cellulose, co-polymers formed between maleic anhydride and methyl vinyl ether, methacrylate derivatives, polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, polyvinyl alcohol and mixtures thereof.

5. The topical gel composition of claim 4 , wherein the gelling agent is carbomer.

6. The topical gel composition of claim 1 , wherein the at least one preservative is selected from the group consisting of methyl paraben, propyl paraben, chlorocresol, thiomersal, sorbic acid, potassium sorbate and mixtures thereof.

7. The topical gel composition of claim 1 , wherein the at least one antioxidant is selected from the group consisting of edetate disodium, sodium sulphite, sodium metabisulfite, propyl gallate, edetate trisodium, tocopherol derivatives, butylated hydroxyl toluene, butylated hydroxyl anisole, ascorbic acid, fumaric acid, malic acid, and citric acid.

8. The topical gel composition of claim 1 , wherein the antioxidant is edetate disodium.

9. The topical gel composition of claim 1 , wherein the salicylic acid ester is selected from the group consisting of methyl salicylate, ethyl salicylate and glycol monosalicylate.

10. The topical gel composition of claim 1 , wherein the acidic and basic agents are selected from the group consisting of sodium hydroxide, potassium hydroxide, ammonia, hydrochloric acid, acetic acid, lactic acid and citric acid.

11. A topical pharmaceutical gel composition suitable for once-a-day application of diclofenac comprising:

at least about 10% w/w of diclofenac sodium;

about 5-25% w/w of a glycol solvent;

about 1-6% w/w of at least one gelling agent;

about 0.01-0.75% w/w of at least one preservative;

about 0.01-1% w/w of at least one antioxidant;

about 1-10% w/w of a salicylic acid ester;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8, wherein the ratio of the amount of diclofenac sodium to the amount of the salicylic acid ester is about 1:0.1 to about 1:0.5.

12. A topical pharmaceutical gel composition suitable for once-a-day application of diclofenac comprising:

at least about 10% w/w of diclofenac sodium;

about 5-25% w/w of a glycol solvent;

about 1-6% w/w of at least one gelling agent;

about 0.01-0.75% w/w of at least one preservative;

about 0.01-1% w/w of at least one antioxidant;

about 1-10% w/w of a salicylic acid ester;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8, wherein the ratio of the amount of diclofenac sodium to the amount of menthol is about 1:0.01 to about 1:0.05.

13. The topical gel composition of claim 1 , wherein the gel is devoid of either C 2 to C 4 alkanol, monoalkyl ether of diethylene glycol, or fatty alcohol.

14. The topical gel composition of claim 1 , wherein once-a-day topical application of said gel composition provides steady state blood levels of diclofenac that are comparable to steady state blood levels of diclofenac achieved with 4 times daily topical application of diclofenac sodium 1% or 3% topical gel.

15. A method for the treatment of painful conditions, inflammations and/or rheumatic diseases comprising topically applying the gel composition of claim 1 to a patient in need thereof.

16. The method of claim 15 , wherein once-a-day topical application of the gel composition provides steady state blood levels of diclofenac that are comparable to steady state blood levels of diclofenac achieved with 4 times daily topical application of diclofenac sodium 1% or 3% topical gel.

17. A topical pharmaceutical gel composition intended for and suitable for once-a-day application of diclofenac consisting of:

about 10-15% w/w of diclofenac sodium;

about 5-25% w/w of a glycol solvent;

about 1-6% w/w of at least one gelling agent;

about 0.01-0.75% w/w of at least one preservative;

about 0.01-1% w/w of at least one antioxidant;

about 1-10% w/w of salicylic acid ester;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8, wherein the ratio of the amount of diclofenac sodium to the amount of the salicylic acid ester is about 1:0.1 to about 1:0.5 and/or the ratio of the amount of diclofenac sodium to the amount of menthol is about 1:0.01 to about 1:0.05.

18. The topical pharmaceutical gel composition of claim 17 consisting of:

about 10-15% w/w of diclofenac sodium;

about 5-25% w/w of propylene glycol as the glycol solvent;

about 1-6% w/w of carbomer as the gelling agent;

about 0.01-0.75% w/w of methyl paraben and propyl paraben as the preservative;

about 0.01-1% w/w of at least one edetate disodium as the antioxidant;

about 1-10% w/w of methyl salicylate as the salicylic acid ester;

about 0.05-1% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

19. The topical pharmaceutical gel composition of claim 18 consisting of:

about 10% w/w of diclofenac sodium;

about 10% w/w of propylene glycol as the glycol solvent;

about 3.5% w/w of carbomer as the gelling agent;

about 0.4% w/w of methyl paraben and propyl paraben as the preservative;

about 0.17% w/w of at least one edetate disodium as the antioxidant;

about 3% w/w of methyl salicylate as the salicylate acid ester;

about 0.2% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

20. The topical pharmaceutical gel composition of claim 18 consisting of:

about 14% w/w of diclofenac sodium;

about 20% w/w of propylene glycol as the glycol solvent;

about 2.5% w/w of carbomer as the gelling agent;

about 0.4% w/w of methyl paraben and propyl paraben as the preservative;

about 0.17% w/w of at least one edetate disodium as the antioxidant;

about 7% w/w of methyl salicylate as the salicylate acid ester;

about 0.3% w/w of menthol;

at least 50% w/w of water; and

at least one acidic and/or basic agent to adjust the pH of the composition to 4-8.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2018
From: LUPIN ATLANTIS HOLDINGS SA
To: LUPIN INC.
Reel/Frame 045855/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2016
From: GAVIS PHARMACEUTICALS, LLC
To: LUPIN ATLANTIS HOLDINGS SA
Reel/Frame 038270/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2014
From: NAYAR, BALA CHANDRAN
To: GAVIS PHARMACEUTICALS
Reel/Frame 034562/0536 →
Continuity (1)
Related Publication 20160166523A1 · Jun 16, 2016